Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Head-to-head randomized trial of infliximab versus etanercept in moderate to severe chronic plaque psoriasis
NL-OMON23276Recruiting
- Sponsor
- Academic Medical Center
- Start
- Jan 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab and etanercept in psoriasis (2 arms), sponsored by Academic Medical Center. Primary endpoints: PASI75 at week 12, PGA at week 12 and 6 more. Started Jan 2009; status: recruiting.
02
Drugs
infliximabetanercept
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON23276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23276.